Bontril Controls Obesity

Bontril (Phendimetrazine tartrate) is the drug that is used to control obesity.

The indication of Phendimetrazine tartrate is given for the management of exogenous obesity by using it for a short-term adjunct, that is, a few weeks in the process of reduction in weight that is based on restricting calories.

The usefulness of the agents of this class is very limited. The possible risk factors that are associated with the use of this drug include symptomatic cardiovascular disease, hyperthyroidism, idiosyncrasy to the sympathomimetic amines, advanced arteriosclerosis, moderate and severe hypertension, known hypersensitivity and glaucoma.

It is found that the development of tolerance to the effect of anorectic drugs occurs within a few weeks. It is strong recommended that when the tolerance is occurred, the users must not exceed the recommended dose in order to get the results earlier. It is suggested that in the case when the tolerance is occurred, the drug use should be stopped.

A hypertensive crisis may result by the use of phendimetrazine tartrate within 14 days that are following by the administration of monoamine oxidase inhibitors. Extreme depression and fatigue are resulted due to the abrupt cessation of the drug administration that has been followed after the prolonged use of very high dosage of the drug.

As phendimetrazine tartrate effects on the central nervous system, there are chances of the impairment of the ability of the patient to get involved in the activities that are considered as potentially hazardous. Those activities are driving motor vehicle and operating machinery.